Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
站內檢索
:::
▍研究室
:::

消化轉譯醫學研究室

TEL: +886-2-28712121 Ext.7434
E-mail: tihuo@vghtpe.gov.tw
主持人：霍德義
學歷：    
1980-1987 國立陽明大學醫學系  霍德義主任
經歷：  
1991－1994 臺北榮民總醫院內科部住院醫師
1994 - 1996 臺北榮民總醫院內科部胃腸科總醫師
1996－1997 臺北榮民總醫院內科部總醫師
2000   美國國家衛生院（NIH）進修
2003 - 2006 國立陽明大學醫學系副教授
現職：  
1997 ~ 迄今 臺北榮民總醫院胃腸科主治醫師
2006 ~ 迄今 國立陽明大學醫學系教授
2006 ~ 迄今 國立陽明大學藥理研究所教授
2017/08 ~ 迄今 國立陽明大學特聘教授
2019/02 ~ 迄今 臺北榮民總醫院醫學研究部 基礎研究科主任
《研究興趣》

肝臟及消化道疾病
《未來研究方向 》

 消化道疾病, 肝炎, 肝硬化及肝癌
《近5年代表著作 》

Publications (since 2016, * indicates corresponding author)

  1. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Chien-Wei Su, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo*. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 2016;64:601-608. (with an editorial)
  2. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection is better than transarterial chemoembolization for patients with hepatocellular carcinoma beyond the Milan criteria: A prognostic nomogram study. Ann Surg Oncol 2016;23:994-1002.
  3. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Yi-You Chiou, Han-Chieh Lin, Teh-Ia Huo*. Surgical resection versus radiofrequency ablation for single hepatocellular carcinoma ≤ 2 cm in a propensity score model. Ann Surg 2016; 263:538-545.
  4. Po-Hong Liu, Teh-Ia Huo*. Reply to “Hepatocellular carcinoma scoring and staging systems: Do we need new tools?” J Hepatol 2016;64:1450-1452.
  5. Po-Hong Liu, Chien-Wei Su, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Yi-Hsiang Huang, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Solitary large hepatocellular carcinoma: Staging and treatment strategy. PLoS One 2016;11: e0155588.
  6. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-Hsiang Huang, Chien-Wei Su, Fa-Yauh Lee, Han-Chieh Lin, Teh-Ia Huo*. Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients. Eur J Cancer 2016;63:25-33.
  7. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Alhareth Al Juboori, Rheun-Chuan Lee, Han-Chieh Lin, Teh-Ia Huo*. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. Liver Int 2016;36:1498-1506.
  8. Chia-Yang Hsu, Teh-Ia Huo*. Nomogram of the Barcelona Clinic Liver Cancer system: on the go. Liver Int 2016;36:1717-1718.
  9. Po-Hong Liu, Teh-Ia Huo*. Utility of prognostic scoring systems in management of hepatocellular carcinoma. Eur J Cancer 2016;68:206-207.
  10. Yu-Wen Su, Po-Hong Liu, Chia-Yang Hsu, Yun-Hsuan Lee, Cheng-Yuan Hsia, Shu-Yein Ho, Ming-Chih Hou, Harn-Shen Chen, Teh-Ia Huo*. Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective. PLoS One 2017;12:e0174333.
  11. Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Yi-You Chiou, MD, Yi-Hsiang Huang, Fa-Yauh Lee, Han-Chieh Lin, Ming-Chih Hou, Teh-Ia Huo*. ALBI and PALBI grade predict survival for hepatocellular carcinoma across treatment modalities and BCLC stages in the MELD era. J Gastroenterol Hepatol 2017;32:879-886.
  12. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Rheun-Chuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Ya-Ju Tsai, Teh-Ia Huo*. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. PLoS One 2017;12:e0180408.
  13. Po-Hong Liu, Teh-Ia Huo*. Treating very early-stage HCC: Have we found the Holy Grail? Ann Surg 2017;266:e31-e32.
  14. Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yun-Hsuan Lee, Teddy S. Nagaria, Rheun-Chuan Lee, Shu-Yein Ho, Ming-Chih Hou, Teh-Ia Huo*. A new treatment-integrated prognostic nomogram of the Barcelona Clinic Liver Cancer system for hepatocellular carcinoma. Sci Rep 2017;7:7914.
  15. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. ALBI score as a novel tool in staging and treatment planning for hepatocellular carcinoma: Is it sufficient? Liver Cancer 2017;6:375-376.
  16. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Yi-You Chiou, Ting-Hui Hsieh, Tom Fang, Ya-Ju Tsai, Ming-Chih Hou, Teh-Ia Huo*. Impact of tumor burden on prognostic prediction for patients with terminal stage hepatocellular carcinoma: A nomogram study. PLoS One 2017;12:e0188031.
  17. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Comment on 'Transarterial chemo-embolisation of hepatocellular carcinoma: Impact of liver function and vascular invasion'. Br J Cancer 2017;117:e5.
  18. Teh-Ia Huo*, Chia-Yang Hsu, Po-Hong Liu. Performance status in patients with HCC: New kid on the block. J Hepatol 2017;67:1352-1353.
  19. Po-Hong Liu, Teh-Ia Huo*. Ablation for hepatocellular carcinoma: Where do we stand? Ann Surg 2017;266:e55-e56.
  20. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-You Chiou, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-Ia Huo*. Prognostic performance of ten liver function models in patients with hepatocellular carcinoma undergoing radiofrequency ablation. Sci Rep 2018;8:843.
  21. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Cheng-Yuan Hsia, Praneeth Kudaravalli, Yun-Hsuan Lee, Yi-You Chiou, Ya-Ju Tsai, Yi-Hsiang Huang, Teh-Ia Huo*. Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma. BMC Cancer 2018;18:289.
  22. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Detecting microvascular invasion in HCC with contrast-enhanced MRI: Is it a good idea? J Hepatol 2018;68:862-863.
  23. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yun-Hsuan Lee, Yi-Hsiang Huang, Fa-Yauh Lee, Ming-Chih Hou, Teh-Ia Huo*. Comparison of twelve liver functional reserve models for outcome prediction in patients with hepatocellular carcinoma undergoing surgical resection. Sci Rep 2018;8:4773.
  24. Teh-Ia Huo*, Chia-Yang Hsu, Po-Hong Liu. Magic mirror on the wall: Which is the best biomarker for hepatocellular carcinoma? Hepatology 2018;67:2482-2483.
  25. Chia-Yang Hsu, Po-Hong Liu, Shu-Yein Ho, Yi-Hsiang Huang, Yun-Hsuan Lee, Rheun-Chuan Lee, Teddy S. Nagaria, Ming-Chih Hou, Teh-Ia Huo*. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the BCLC system. Liver Int 2018;38:1803-1811.
  26. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Jhen He, Yun-Hsuan Lee, Yi-Hsiang Huang, Ming-Chih Hou, Teh-Ia Huo*. Current noninvasive liver reserve models do not predict histological fibrosis severity in hepatocellular carcinoma. Sci Rep 2018;8:15074.
  27. Yun-Cheng Hsieh, Kuei-Chuan Lee, Ying-WenWang, Ying-Ying Yang, Ming-Chih Hou, Teh-Ia Huo*, Han-Chieh Lin*. Correlation and prognostic accuracy between noninvasive liver fibrosis markers and portal pressure in cirrhosis: Role of ALBI score. PLoS One 2018;13: e0208903.
  28. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Staging and restaging for hepatocellular carcinoma: Solution of confusion? Hepatology 2019;69:464-5.
  29. Teh-Ia Huo*. ALBI grade as a new player in hepatocellular carcinoma. J Chin Med Assoc 2019;82:1.
  30. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Predicting post-resection recurrence of hepatocellular carcinoma: Spleen stiffness vs ALBI grade. J Hepatol 2019;70:808.
  31. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Hsiang Huang, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin (ALBI) grade-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Eur J Surg Oncol 2019;45:776-781.
  32. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Chien-Wei Su, Yi-Hsiang Huang, Hao-Jan Lei, Yi-Jhen He, Ming-Chih Hou, Teh-Ia Huo*. An albumin-bilirubin (ALBI) grade-based prognostic model for patients with hepatocellular carcinoma within Milan criteria. Am J Clin Oncol 2019;42:698-704.
  33. Ping-Hsing Tsai, Yueh Chien, Mong-Lien Wang, Chih-Hung Hsu, Benoit Laurent, Shih-Jie Chou, Wei-Chao Chang, Chian-Shiu Chien, Hsin-Yang Li, Hsin-Chen Lee, Teh-Ia Huo (co-first author), Jui-Hung Hung, Chung-Hsuan Chen, Shih-Hwa Chiou. Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. Nucleic Acids Res 2019; 47:10115-10133.
  34. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Hao-Jan Lei, Yi-Hsiang Huang, Chih-Chieh Ko, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin grade-based nomogram of the BCLC system for personalized prognostic prediction in hepatocellular carcinoma. Liver Int 2020;40:205-214.
  35. Teh-Ia Huo*, Shu-Yein Ho. Evolution of hepatocellular carcinoma: Non-B, non-C and beyond. J Gastroenterol 2020;55:123-124.
  36. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Hao-Jan Lei, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. A new prognostic model based on albumin-bilirubin grade for hepatocellular carcinoma beyond the Milan criteria. Dig Dis Sci 2020;65:658-667.
  37. Teh-Ia Huo*, Po-Hong Liu. Too many vs too few platelets in patients with hepatocellular carcinoma: Good or bad? Liver Cancer 2020;9:108-109.
  38. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Hao-Jan Lei, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Sci Rep 2020;10:3925.
  39. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Nomogram to predict surgical hepatocellular carcinoma with Child-Pugh B: Feasibility and overlooked predictors. J Hepatol 2020;72:1032-1033.
  40. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Survival of patients with hepatocellular carcinoma in renal insufficiency: Prognostic role of albumin-bilirubin grade. Cancers 2020;12:1130.
  41. Teh-Ia Huo*, Po-Hong Liu, Shu-Yein Ho. Are inflammation-based models feasible tools in predicting the outcome of patients with hepatocellular carcinoma? Liver Int 2020; 40:1498.
  42. I-Cheng Lee, Teh-Ia Huo*, Yi-Hsiang Huang*. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc 2020;83:521-523.
  43. Shu-Yein Ho, Lei-Chi Wang, Chia-Yang Hsu, Po-Hong Liu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Teh-Ia Huo*. Metavir fibrosis stage in hepatitis C-related hepatocellular carcinoma and association with noninvasive liver reserve models. J Gastrointest Surg 2020;24:1860-1862.
  44. Po-Hong Liu, Chia-Yang Hsu, Chien-Wei Su, Yi-Hsiang Huang, Ming-Chih Hou, Nicole E. Rich, Naoto Fujiwara, Yujin Hoshida, Amit Singal*, Teh-Ia Huo*. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-2534.
  45. Teh-Ia Huo*, Shu-Yein Ho, Chih-Chieh Ko. Stereotactic body radiation therapy vs. radiofrequency ablation for HCC: More questions than answers. J Hepatol 2020;73:972-973.
  46. Shu-Yein Ho, Mei-Hsia Yuan, Chu-Chieh Chen, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Hao-Jan Lei, Rheun-Chuan Lee, Teh-Ia Huo*. Differential survival impact of diabetes mellitus on hepatocellular carcinoma: Role of staging determinants. Dig Dis Sci 2020;65:3389-3402.
  47. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Tumor burden score for hepatocellular carcinoma: Is it an authentic prognostic marker? Br J Surg 2020;107:e625.
  48. Teh-Ia Huo*, Po-Hong Liu, Shu-Yein Ho. Treating small hepatocellular carcinoma: Stereotactic body radiation therapy vs radiofrequency ablation. J Gastroenterol Hepatol 2020;35:2020.
  49. Yi-Ying Lin, Yi-Ping Yang, Wei-Yi Lai, Chian-Shiu Chien, Shih-Jen Chen, De-Kuang Hwang, Ying-Hsiu Lai, Tai-Chi Lin, Shih-Hwa Chiou, Yu-Li Lo, Teh-Ia Huo*, Yueh Chien*. Development of polydimethylsiloxane-based biomimetic scaffolds with cylinder micropillars for retinal pigment epithelial cell cultivation. J Chin Med Assoc 2020;83: 1029-1033.
  50. Teh-Ia Huo*, Shu-Yein Ho, Chia-Yang Hsu. Microvascular invasion as a prognostic predictor in hepatocellular carcinoma: How accurate is it? Liver Cancer 2020;9:787-788.
  51. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Is computed tomography-enhanced clinical significant portal hypertension surrogate an authentic prognostic predictor for surgical hepatocellular carcinoma? J Gastroenterol Hepatol 2020;35:2289.
  52. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Changing patterns of etiology and management of hepatocellular carcinoma: Need for global reappraisal. J Gastroenterol 2021;56:406-407.
  53. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Predicting microvascular invasion in HCC with ctDNA: What are the pitfalls? Liver Int 2021;41:1148-1149.
  54. Shu-Yein Ho, Chia-Yang Hsu, Po-Hong Liu, Rheun-Chuan Lee, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin (ALBI) grade-based nomogram for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Dig Dis Sci 2021;66:1730-1738.
  55. Teh-Ia Huo*, Shu-Yein Ho, Ping-Hsin Tsai. Post hepatitis B-eliminated hepatocellular carcinoma: New challenges. Liver Int 2021;41:1173-1174.
  56. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Cheng-Yuan Hsia, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Albumin-bilirubin (ALBI) grade in dialysis patients with hepatocellular carcinoma: Prognostic impact and staging strategy. J Gastrointest Oncol 2021;12:722-734.
  57. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Changing faces of hepatocellular carcinoma: East vs West. Liver Int 2021;41:1430-1431.
  58. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Comment on effect of microvascular invasion risk on early recurrence of hepatocellular carcinoma after surgery and radiofrequency ablation. Ann Surg 2021;274:e101-e102.
  59. Teh-Ia Huo*, Po-Hong Liu, Chia-Yang Hsu. Using circulating biomarkers to stage hepatocellular carcinoma: Pitfalls and limitations. Hepatology 2021;73:2611.
  60. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Selecting an optimal prognostic model for advanced hepatocellular carcinoma: Any new ideas? Dig Liver Dis 2021; 53:1208-1209.
  61. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Cheng-Yuan Hsia, Ping-Hsing Tsai, Shih-Jie Chou, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Easy albumin-bilirubin score as a new prognostic predictor in hepatocellular carcinoma. Hepatol Res 2021;51:1129-1138.
  62. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Chih-Chieh Ko, Yi-Hsiang Huang, Chien-Wei Su, Rheun-Chuan Lee, Ping-Hsing Tsai, Ming-Chih Hou, Teh-Ia Huo*. Tumor burden score as a new prognostic marker for patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Gastroenterol Hepatol 2021; 36:3196-3203.
  63. Teh-Ia Huo*, Shu-Yein Ho, Jia-I Liao. Improved patient survival in hepatitis C virus-related hepatocellular carcinoma: Do direct-acting antivirals play a role? J Gastroenterol Hepatol 2021;36:3557.
  64. Teh-Ia Huo*, Shu-Yein Ho, Chih-Chieh Ko. Nomogram for surgical hepatocellular carcinoma: What have we missed? Liver Int 2021;41:3034-3035.
  65. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Jia-I Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo*. A new tumor burden score and albumin-bilirubin grade-based prognostic model for hepatocellular carcinoma. Cancers 2022;14:649.
  66. Teh-Ia Huo*, Shu-Yein Ho, Jia-I Liao. Improving the accuracy of outcome prediction for hepatocellular carcinoma: Asia strategies. Liver Int 2022;42:714-715.
  67. Teh-Ia Huo*, Jia-I Liao, Shu-Yein Ho. Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet? J Hepatol 2022;76:987-988.
  68. Chih-Chieh Ko, Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Cheng-Yuan Hsia, Yi-Hsiang Huang, Chien-Wei Su, Hao-Jan Lei, Rheun-Chuan Lee, Ming-Chih Hou, Teh-Ia Huo*. Dual hepatitis B and C-associated hepatocellular carcinoma: Clinical characteristics, outcome, and prognostic role of albumin-bilirubin grade. Int J Clin Oncol 2022;27:739-748.
  69. Teh-Ia Huo*, Jia-I Liao, Shu-Yein Ho. 3-Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor? Liver Int 2022; 42:1475.
  70. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Jia-I Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo*. Radiofrequency ablation versus transarterial chemoembolization for hepatocellular carcinoma within Milan criteria: Prognostic role of tumor burden score. Cancers 2022;14:4207.
  71. Teh-Ia Huo*, Shu-Yein Ho, Jia-I Liao. Comment on: Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. Br J Surg 2022;109:e119.
  72. Teh-Ia Huo*, Shu-Yein Ho, Jia-I Liao. A commentary on “Prothrombin induced by vitamin K Absence-II versus alpha-fetoprotein in detection of both resectable hepatocellular carcinoma and early recurrence after curative liver resection: A retrospective cohort study”. Int J Surg 2022;106:106910.
  73. Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Jia-I Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo*. Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: Role of albumin-bilirubin (ALBI) grade vs easy ALBI grade. Expert Rev Gastroenterol Hepatol 2022;16:903-0911.
  74. Teh-Ia Huo*, Shu-Yein Ho, Chia-Yang Hsu. Look for a physical health status surrogate in hepatocellular carcinoma: Have we found the Holy Grail? Clin Gastroenterol Hepatol 2022;20:2923.
  75. Teh-Ia Huo*, Shu-Yein Ho, Po-Hong Liu. Changing epidemiological features of hepatocellular carcinoma: Taiwan’s position. Liver Int 2022;42:2911.

最後更新：

回到最上